This article was originally published in The Gray Sheet
Executive SummaryIs "hopeful" that a premarket approval application for its Twenty/Twenty excimer laser for phototherapeutic keratectomy will be reviewed at the next meeting of FDA's Ophthalmic Devices Panel, scheduled for March 21-22. Use of the excimer laser for PTK "was one subject discussed during a closed door session" of the panel last October, the company says in its third quarter 1993 report
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.